HeXun Biosciences Co Ltd

As of June 30, 2026, HeXun Biosciences Co Ltd carries a market capitalization of 2.42B, placing it among publicly traded companies globally. Its enterprise value stands at 1.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HeXun Biosciences Co Ltd's next confirmed earnings release is scheduled for March 12, 2027.

As of June 30, 2026, HeXun Biosciences Co Ltd has 52.13M shares outstanding.

As of June 30, 2026, HeXun Biosciences Co Ltd trades at a trailing price-to-earnings ratio of 18.40. The price-to-sales ratio is 6.94, and the price-to-book ratio stands at 2.26.

As of June 30, 2026, HeXun Biosciences Co Ltd trades at an EV/EBITDA multiple of 10.06 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. HeXun Biosciences Co Ltd trades at an EV/FCF ratio of 12.15, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.62B versus a market cap of 2.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HeXun Biosciences Co Ltd maintains a current ratio of 12.14, meaning it holds 12.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.24, indicating elevated leverage, while an interest coverage ratio of 151.64 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, HeXun Biosciences Co Ltd posted a return on equity (ROE) of 13.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.58 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.85, useful for judging operating efficiency across full business cycles. The company generates approximately 5.87M in revenue per employee across its workforce of 52.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.38 indicates how many times HeXun Biosciences Co Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, HeXun Biosciences Co Ltd recorded 24.89M in income tax expense. That works out to an effective tax rate of 17.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 141.21M, leaving 116.33M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, HeXun Biosciences Co Ltd's stock has declined approximately 23.83% over the past 52 weeks. The 50-day moving average sits at 42.96, while the 200-day moving average is 53.49.

Over the twelve months ended June 30, 2026, HeXun Biosciences Co Ltd generated 308.21M in revenue and converted that into 116.33M in net income, yielding earnings per share of 2.51. EBITDA reached 161.19M, while operating income came in at 130.56M.

As of June 30, 2026, HeXun Biosciences Co Ltd holds 828.93M in cash and equivalents against 34.66M in total debt, resulting in a net debt position of -417.77M. Total book value stands at 1.07B, with working capital of 877.92M providing operational flexibility.

HeXun Biosciences Co Ltd produced 163.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.15M in capital expenditures, free cash flow totaled 132.65M - equivalent to 2.87 per share.

Over the twelve months ended June 30, 2026, HeXun Biosciences Co Ltd posted a gross margin of 90.97, reflecting its pricing power and cost economics. The operating margin of 42.36 and net profit margin of 37.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.18, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -10.94, meaning HeXun Biosciences Co Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, HeXun Biosciences Co Ltd has an Altman Z-Score of 14.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.